Yingxiao Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingxiao Shi has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- David R. Liu
Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
15 shared publications - Adam Kashishian
Gilead Sciences, Foster City, California
11 shared publications - Benjamin J. Wolf
Gilead Sciences, Foster City, California
11 shared publications - Caroline G. Fahey
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
11 shared publications - Choudhury Fabliha B. Yusuf
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
11 shared publications - Cloud P. Paweletz
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
11 shared publications
Latest Publications
- Open Access
Genomic classification and immune profiling define mucosal melanoma
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.
Open AccessGenomic classification and immune profiling define mucosal melanoma
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.
- Open Access
- 16 July 2026
- Published by Elsevier in SSRN Electronic Journal
Immunogenic Tumor Mass Dormancy as a Driver of Persistent Residual Lesions in Immunotherapy-Treated Melanoma
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.
- 16 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImmunogenic Tumor Mass Dormancy as a Driver of Persistent Residual Lesions in Immunotherapy-Treated Melanoma
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.
- Open Access
- 30 June 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Restraint of melanoma progression by cells in the local skin environment
Keratinocytes, the dominant cell type in the melanoma microenvironment during tumor initiation, exhibit diverse effects on melanoma progression. Using a zebrafish model of melanoma and human cell co-cultures, we observed that keratinocytes undergo an epithelial-mesenchymal transition (EMT)-like transformation in the presence of melanoma, reminiscent of their behavior during wound healing. Surprisingly, overexpression of the EMT-transcription factor Twist in keratinocytes led to improved overall survival in zebrafish melanoma models, despite no change in tumor initiation rates. This survival benefit was attributed to reduced melanoma invasion, as confirmed by human cell co-culture assays. Single-cell RNA-sequencing revealed a unique melanoma cell cluster in the Twist-overexpressing condition, exhibiting a more differentiated, less invasive phenotype. Further analysis nominated homotypic jam3b–jam3b and pgrn–sort1a interactions between Twist-overexpressing keratinocytes and melanoma cells as potential mediators of the invasive restraint. Our findings suggest that EMT in the tumor microenvironment may paradoxically limit melanoma invasion through altered cell–cell interactions.
- 30 June 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessRestraint of melanoma progression by cells in the local skin environment
Keratinocytes, the dominant cell type in the melanoma microenvironment during tumor initiation, exhibit diverse effects on melanoma progression. Using a zebrafish model of melanoma and human cell co-cultures, we observed that keratinocytes undergo an epithelial-mesenchymal transition (EMT)-like transformation in the presence of melanoma, reminiscent of their behavior during wound healing. Surprisingly, overexpression of the EMT-transcription factor Twist in keratinocytes led to improved overall survival in zebrafish melanoma models, despite no change in tumor initiation rates. This survival benefit was attributed to reduced melanoma invasion, as confirmed by human cell co-culture assays. Single-cell RNA-sequencing revealed a unique melanoma cell cluster in the Twist-overexpressing condition, exhibiting a more differentiated, less invasive phenotype. Further analysis nominated homotypic jam3b–jam3b and pgrn–sort1a interactions between Twist-overexpressing keratinocytes and melanoma cells as potential mediators of the invasive restraint. Our findings suggest that EMT in the tumor microenvironment may paradoxically limit melanoma invasion through altered cell–cell interactions.
- Open Access
STITCH links cellular morphology and gene expression in spatial transcriptomics
In situ spatial (ISS) sequencing can uncover co-variation between cellular morphology and gene expression in vivo. However, a principled and interpretable mathematical representation of morphology has not yet been applied in this context. In particular, current deep learning-based representations of cell images confound a cell’s shape with its size. We present an interpretable representation of cellular boundary contours, based on tangent principal component analysis (TPCA) in a Kendall shape manifold, that captures size-independent contour shape features. This approach successfully recovers shape-perturbing genes in an RNAi screen than a previous metric geometry-based approach. We build on TPCA to develop STITCH (Shape–TranscriptomIc Correlation and Harmonization), an approach to reveal covariation between cell morphology with gene expression in ISS datasets. In a Xenium dataset, STITCH outperforms a deep learning-based approach in both recovering the layered organization of keratinocytes and a spatial gradient in nuclear eccentricity. Across samples in a melanoma CosMx dataset, STITCH reproducibly associates elongated and triangular fibroblasts with proximity to malignant cells and myofibroblast-like transcriptional program. Finally, STITCH independently recovers a known link between mesenchymal-like malignant cell states and increased cell area in two melanoma cohorts. STITCH can thus yield interpretable morphology–transcriptome relationships across cell types, patients, and spatial transcriptomics platforms.
Open AccessSTITCH links cellular morphology and gene expression in spatial transcriptomics
In situ spatial (ISS) sequencing can uncover co-variation between cellular morphology and gene expression in vivo. However, a principled and interpretable mathematical representation of morphology has not yet been applied in this context. In particular, current deep learning-based representations of cell images confound a cell’s shape with its size. We present an interpretable representation of cellular boundary contours, based on tangent principal component analysis (TPCA) in a Kendall shape manifold, that captures size-independent contour shape features. This approach successfully recovers shape-perturbing genes in an RNAi screen than a previous metric geometry-based approach. We build on TPCA to develop STITCH (Shape–TranscriptomIc Correlation and Harmonization), an approach to reveal covariation between cell morphology with gene expression in ISS datasets. In a Xenium dataset, STITCH outperforms a deep learning-based approach in both recovering the layered organization of keratinocytes and a spatial gradient in nuclear eccentricity. Across samples in a melanoma CosMx dataset, STITCH reproducibly associates elongated and triangular fibroblasts with proximity to malignant cells and myofibroblast-like transcriptional program. Finally, STITCH independently recovers a known link between mesenchymal-like malignant cell states and increased cell area in two melanoma cohorts. STITCH can thus yield interpretable morphology–transcriptome relationships across cell types, patients, and spatial transcriptomics platforms.
- Open Access
Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF -Mutant Melanoma
BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti–PD-1/anti-CTLA-4) have transformed the treatment of BRAF -mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. In this study, we analyzed pre-treatment tumor samples from a clinically annotated cohort of 155 patients with BRAF -mutant metastatic melanoma treated with first-line BRAFi/MEKi and followed for up to five years. We stratified patients into durable responders (PFS ≥ 24 months) and rapid progressors (PFS < 6 months with progression) and found that a global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished these groups. Combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase (LDH) or radiographic lesion dimensions), we developed a parsimonious model that predicted durable responders with high precision and specificity. Notably, the analogous population of patients treated instead with immunotherapy were not durable responders, suggesting that the selected predictors of durable responders are targeted therapy specific. Spatial profiling of a subset of pre-treatment biopsies (n = 47) demonstrated that high intratumoral, but not peritumoral, CD8 + T-cell infiltration correlated with prolonged survival on BRAF-targeted therapy and served as an independent predictive factor when considered with genomic heterogeneity and features of clinical tumor burden. Together, these findings highlight the distinct baseline intrinsic and extrinsic features underlying durable response to BRAF-targeted therapy and support their potential implication in guiding treatment selection for patients with BRAF -mutant metastatic melanoma. One-Sentence Summary: Integrated clinical, tumor genomic, and immune microenvironmental features predict durable responses to BRAF-targeted therapy.
Open AccessGenomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in BRAF -Mutant Melanoma
BRAF-targeted therapy (BRAFi/MEKi) and immune checkpoint blockade (anti–PD-1/anti-CTLA-4) have transformed the treatment of BRAF -mutant metastatic melanoma. While most patients who respond to targeted therapy eventually progress, a subset derives durable benefit, and biomarkers to identify this subset would inform optimal treatment selection. In this study, we analyzed pre-treatment tumor samples from a clinically annotated cohort of 155 patients with BRAF -mutant metastatic melanoma treated with first-line BRAFi/MEKi and followed for up to five years. We stratified patients into durable responders (PFS ≥ 24 months) and rapid progressors (PFS < 6 months with progression) and found that a global metric of tumor genomic heterogeneity, rather than individual gene alterations, distinguished these groups. Combining genomic heterogeneity with baseline tumor burden (e.g., lactate dehydrogenase (LDH) or radiographic lesion dimensions), we developed a parsimonious model that predicted durable responders with high precision and specificity. Notably, the analogous population of patients treated instead with immunotherapy were not durable responders, suggesting that the selected predictors of durable responders are targeted therapy specific. Spatial profiling of a subset of pre-treatment biopsies (n = 47) demonstrated that high intratumoral, but not peritumoral, CD8 + T-cell infiltration correlated with prolonged survival on BRAF-targeted therapy and served as an independent predictive factor when considered with genomic heterogeneity and features of clinical tumor burden. Together, these findings highlight the distinct baseline intrinsic and extrinsic features underlying durable response to BRAF-targeted therapy and support their potential implication in guiding treatment selection for patients with BRAF -mutant metastatic melanoma. One-Sentence Summary: Integrated clinical, tumor genomic, and immune microenvironmental features predict durable responses to BRAF-targeted therapy.
- Open Access
Immunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.
Open AccessImmunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.
- Open Access
Spatial determinants of tumor cell dedifferentiation and plasticity in primary cutaneous melanoma
Localized cutaneous melanoma can be cured by excision but success critically depends on early detection and risk assessment of primary lesions. However, their initiation, progression, and immunology remain poorly understood, partly due to high intra- and inter-tumor heterogeneity. We studied this heterogeneity using spatial profiling in over 300 histological domains, each representing a single progression stage, and found that 200-600 cell neighborhoods from a single melanoma can be as different in RNA and protein expression as neighborhoods from different tumors. These differences are not stochastic, however, and disease progression can be mapped at the neighborhood level onto a cell state landscape defined by the activity of the melanocyte master regulator MITF and genes associated with a dedifferentiated neural crest phenotype. Position in this landscape is influenced by proximity to immune cells, perivascular environments, and other tissue features, but no single association is absolute, giving rise to complex spatial patterns.
Open AccessSpatial determinants of tumor cell dedifferentiation and plasticity in primary cutaneous melanoma
Localized cutaneous melanoma can be cured by excision but success critically depends on early detection and risk assessment of primary lesions. However, their initiation, progression, and immunology remain poorly understood, partly due to high intra- and inter-tumor heterogeneity. We studied this heterogeneity using spatial profiling in over 300 histological domains, each representing a single progression stage, and found that 200-600 cell neighborhoods from a single melanoma can be as different in RNA and protein expression as neighborhoods from different tumors. These differences are not stochastic, however, and disease progression can be mapped at the neighborhood level onto a cell state landscape defined by the activity of the melanocyte master regulator MITF and genes associated with a dedifferentiated neural crest phenotype. Position in this landscape is influenced by proximity to immune cells, perivascular environments, and other tissue features, but no single association is absolute, giving rise to complex spatial patterns.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure S1 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Supplementary figureS1 shows the figures related to Figure 1.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S1 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Supplementary figureS1 shows the figures related to Figure 1.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure S1 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Supplementary figureS1 shows the figures related to Figure 1.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S1 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Supplementary figureS1 shows the figures related to Figure 1.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure S3 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Supplementary figureS3 shows the figures related to Figure 3.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure S3 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Supplementary figureS3 shows the figures related to Figure 3.